Phase I Study of Trametinib and Nab-paclitaxel in Patients With Melanoma
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 29 Jan 2016
At a glance
- Drugs Paclitaxel (Primary) ; Trametinib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors SCRI Development Innovations
- 14 Jan 2016 Status changed from not yet recruiting to withdrawn prior to enrolment as per ClinicalTrials.gov record.
- 09 Oct 2015 Planned End Date changed from 1 Nov 2017 to 1 Nov 2018 as per ClinicalTrials.gov record.
- 09 Oct 2015 Planned primary completion date changed from 1 Jul 2017 to 1 Mar 2018 as per ClinicalTrials.gov record.